From guiding older patients on National Immunisation Program (NIP) stock to clarifying second-dose rules, here’s what pharmacists need to know about the 2025 influenza...

Two experts set out how to deal with patient and pharmacist anxiety over myriad recent changes.

Despite being one of the most common phenotypes with a high clinical burden, hand OA was long regarded as a ‘forgotten disease’, with limited clinical evidence to guide treatment recommendations.

From prescribing rights to aged care roles, the 2025 federal election could usher in pharmacy-led healthcare reform.

A cheap and widely used corticosteroid may be employed by Australian doctors in the treatment of seriously ill COVID-19 patients.

On 11 July, millions of Australians gained access to oral COVID-19 antiviral treatments after the eligibility criteria widened significantly.